Please assess the completion status of the following clinical trial:

Trial Title: The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males or non-pregnant, non-lactating females who are 18 years or older~* Laboratory-proven acute Q fever since the year 2007 and/or positive serology fitting a past infection with Coxiella burnetii;~* AND being severely fatigued, defined by scoring 35 or higher on the subscale fatigue severity of the CIS;~* AND being fatigued for at least 6 months;~* AND disabled because of the fatigue, defined by scoring 450 or higher on the SIP~* Subjects must sign a written informed consent form.~Exclusion Criteria:~* Fulfilling criteria for chronic Q fever, namely:~  * IFA IgG fase I ≥ 1024, ≥ 3 months after acute Q fever and/or~ * Positive Coxiella burnetii PCR on serum or tissue, 1 month after acute Q fever~* Acute Q fever in the setting of a prosthetic cardiac valve or aneurysm surgery or stenting necessitating prophylactic use of doxycycline;~* Pregnancy or unwillingness to use effective contraceptives during the entire study period;~* Imminent death;~* Inability to give informed consent;~* Allergy or intolerance to doxycycline;~* Somatic or psychiatric illness that could explain the chronic fatigue;~* Subjects who are currently enrolled on other investigational drug trials or receiving investigational agents;~* Receiving antibiotics for more than 4 weeks, potentially active against Coxiella burnetii, for any other reason since Q-fever diagnosis;~* Subjects who are receiving and cannot discontinue barbiturates, phenytoin, or carbamazepine (these drugs may increase the metabolism of doxycycline and therefore reducing half-life of doxycycline);~* Moderate or severe liver disease (AF, ALAT, ASAT \> 3 times the upper limit of normal).~* Current engagement in a legal procedure concerning financial benefits (only current involvement interferes with the effectivity of cognitive behavioral therapy. Once the appeal procedure ends, subjects can be included)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cognitive behavioral therapy (Type: EXPERIMENTAL): None
- Doxycycline (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).